Stockscreener 앱 받기
5.39
1.32%
0.07
시장 영업 전:
5.47
0.08
+1.48%
Compass Therapeutics Inc 주식(CMPX)의 최신 뉴스
Compass Therapeutics: Potential Here, But Patience Required (NASDAQ:CMPX) - Seeking Alpha
Compass Therapeutics, Inc. (NASDAQ:CMPX) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Will Compass Therapeutics Inc stock go up in YEARWeekly Trade Summary & Fast Moving Market Watchlists - baoquankhu1.vn
Compass Therapeutics, Inc.Common Stock (NQ: CMPX - The Chronicle-Journal
Investment Advisor Bets Big on CMPX Stock, Adds 2.5 Million Shares, According to Latest SEC Filing - AOL.com
Here's why Compass Therapeutics, Inc. (CMPX) is a great momentum stock to buy - MSN
Compass Therapeutics Sees Major Institutional Investment Boost - National Today
Compass Therapeutics, Inc. $CMPX Stock Position Lifted by Suvretta Capital Management LLC - MarketBeat
Cantor Fitzgerald Maintains Overweight on CMPX (Compass Therapeutics, Inc.), Mar 2026 - Meyka
Is Compass Therapeutics' (CMPX) New ESOP Shelf Offering Reframing Its Equity-Funded R&D Strategy? - Sahm
Compass Therapeutics Inc celebrates women leadership driving innovation in science and therapy development - Traders Union
Compass Therapeutics stock rating reaffirmed at Citizens on trial progress By Investing.com - Investing.com Canada
What Compass Therapeutics (CMPX)'s Pipeline Progress And 2025 Losses Reveal About Its Oncology Strategy - Yahoo Finance
HC Wainwright Has Positive Estimate for CMPX FY2026 Earnings - MarketBeat
Wedbush Keeps Their Buy Rating on Compass Therapeutics (CMPX) - The Globe and Mail
What is HC Wainwright's Estimate for CMPX Q1 Earnings? - MarketBeat
Jefferies raises Compass Therapeutics stock price target on trial progress - Investing.com Australia
Jefferies raises Compass Therapeutics stock price target on trial progress By Investing.com - Investing.com Australia
Compass Therapeutics stock holds Outperform at William Blair ahead of trial data - Investing.com Canada
Raymond James reiterates Compass Therapeutics stock Outperform rating By Investing.com - Investing.com Canada
Raymond James reiterates Compass Therapeutics stock Outperform rating - Investing.com
Compass Therapeutics Reports 2025 Financial Results and Provides Corporate Update - Investing News Network
Compass Therapeutics (NASDAQ:CMPX) Releases Earnings Results, Beats Estimates By $0.01 EPS - MarketBeat
Compass Therapeutics Inc. reports results for the quarter ended December 31Earnings Summary - TradingView
Compass Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 - marketscreener.com
Compass Therapeutics' Q4 Net Loss Narrows - marketscreener.com
Earnings Flash (CMPX) Compass Therapeutics Posts Q4 Net Loss $0.09 a Share, vs. FactSet Est of $0.09 Loss - marketscreener.com
Compass Therapeutics' 2025 net loss widens as R&D costs jump - TradingView
Compass Therapeutics 10-K: $0.0M Revenue, $(0.42) EPS on $(66.5)M Net Loss - TradingView
CMPX: Tovecimig achieved 17.1% ORR in 2L BTC, with pivotal data and filings expected in 2026 - TradingView
How Palo Alto’s New Stake and Rising Institutional Ownership At Compass Therapeutics (CMPX) Has Changed Its Investment Story - simplywall.st
Assessing Compass Therapeutics (CMPX) Valuation As CTX-009 Gains Attention In Biliary Tract Cancer Market - Yahoo Finance
Monashee Investment Management Boosts Stake in Compass Therapeutics - National Today
Signal Recap: Does Compass Therapeutics Inc have a competitive edgeQuarterly Performance Summary & Real-Time Chart Pattern Alerts - baoquankhu1.vn
Monashee Investment Management LLC Has $4.38 Million Stake in Compass Therapeutics, Inc. $CMPX - MarketBeat
Compass Therapeutics, Inc. (CMPX) Stock Analysis: Exploring a 130% Potential Upside in Biotech - DirectorsTalk Interviews
Compass Therapeutics earnings on deck as pivotal cancer data looms By Investing.com - Investing.com Canada
Compass Therapeutics earnings on deck as pivotal cancer data looms - Investing.com
Compass Therapeutics Inc. expected to post a loss of 9 cents a shareEarnings Preview - TradingView
Compass Therapeutics, Inc. (NASDAQ:CMPX) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Zacks.com Spotlights Orla Mining, FIGS, and Compass Therapeutics - Intellectia AI
Is Compass Therapeutics Inc. stock forming a cup and handleJuly 2025 Retail & Reliable Entry Point Trade Alerts - mfd.ru
Compass Therapeutics Moves CTX-10726 Into the Clinic: What Early Investors Should Know - TipRanks
Analysts Offer Insights on Healthcare Companies: Eton Pharmaceuticals (ETON), Guardant Health (GH) and Compass Therapeutics (CMPX) - The Globe and Mail
Compass Therapeutics (CMPX) to Release Quarterly Earnings on Thursday - MarketBeat
Is Compass Therapeutics, Inc. (CMPX) Outperforming Other Medical Stocks This Year? - Yahoo Finance
Support Test: Can Compass Therapeutics Inc. sustain its profitabilityOil Prices & Weekly Return Optimization Alerts - mfd.ru
Bearish Setup: Will Compass Therapeutics Inc stock go up in YEAREarnings Miss & Free Real-Time Market Sentiment Alerts - baoquankhu1.vn
1.20%
0.06%
자본화:
|
볼륨(24시간):